Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone vs placebo plus prednisone in metastatic castration-resistant prostate cancer after docetaxel
2007-005837-13Phase 3Completed
- Sponsor
- Cougar Biotechnology
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Abiraterone acetate plus prednisone with Placebo plus prednisone (2 arms). Primary endpoint: Overall survival. Started Apr 2008; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2007-005837-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005837-13.